CK-3773274 (5 - 20 mg) ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 58 | 肥大型心筋症 | 1 |
58. 肥大型心筋症
臨床試験数 : 126 / 薬物数 : 135 - (DrugBank : 42) / 標的遺伝子数 : 46 - 標的パスウェイ数 : 162
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04848506 (ClinicalTrials.gov) | May 6, 2021 | 9/4/2021 | CY 6022 is an Open Label Study to Collect Long-term Safety and Tolerability Data for Aficamten (CK-3773274) | An Open-Label Study of CK-3773274 for Patients With Symptomatic Hypertrophic Cardiomyopathy (HCM) | Symptomatic Hypertrophic Cardiomyopathy (HCM) | Drug: CK-3773274 (5 - 20 mg) | Cytokinetics | NULL | Enrolling by invitation | 18 Years | 85 Years | All | 300 | Phase 2 | Italy;United States;Poland;Spain |